Press Releases Year None202320222021202020192018 Jun 01, 2023 Vaxcyte to Present at the Jefferies Healthcare Conference May 08, 2023 Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update May 03, 2023 Vaxcyte to Present at the BofA Securities 2023 Health Care Conference Apr 21, 2023 Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 19, 2023 Vaxcyte Announces Pricing of $500 Million Public Offering Apr 17, 2023 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Apr 17, 2023 Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies Apr 16, 2023 Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies Mar 30, 2023 Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Feb 27, 2023 Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
Year None202320222021202020192018 Jun 01, 2023 Vaxcyte to Present at the Jefferies Healthcare Conference May 08, 2023 Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update May 03, 2023 Vaxcyte to Present at the BofA Securities 2023 Health Care Conference Apr 21, 2023 Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 19, 2023 Vaxcyte Announces Pricing of $500 Million Public Offering Apr 17, 2023 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Apr 17, 2023 Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies Apr 16, 2023 Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies Mar 30, 2023 Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Feb 27, 2023 Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
